Down more than 6% at one point, GE stock ended the day in positive territory. Why?
An upgrade is driving Stratasys, Inc. higher, but that may not lead to a long-term winner for investors.
Investors are cheering the FDA's surprisingly progressive take on uniQure's novel hemophilia B gene therapy candidate.
The payment and banking solutions company's third quarter was held back by challenges in the ATM market.
A phase 3 failure sent shares down.
Are cost pressures worrying some investors?
The software company put up some fantastic first-quarter numbers, and it sees more growth ahead.
Profit growth returned in a big way for the sneaker maker.
The Swedish telecom equipment maker's tides are turning, as seen in the latest earnings report.
News that layoffs are underway overshadowed mixed earnings results.
Revenues were down, and profits down even more.
Agenus' $250 million mixed shelf offering caused investors to hit the exits today.
The harsh reality of launching a novel medical device is starting to weigh on TransEnterix's shares.
Here are the key figures behind Genuine Parts' disappointing results.
The creative software leader touched a fresh all-time high after offering impressive guidance for the year ahead.
The company released preliminary results, but volatility since a patent-case win against Apple may be the main driver.
Why is the company taking on debt to simply pay it out to shareholders in a special dividend?
The tanker company continued its streak of paying a dividend but it was the lowest one in its history.
Shares rally after the company reports encouraging results from a phase 2 trial.
The diversified driller is diluting investors.
Sometimes, your guess is really as good as anybody else's.
The AI platform company jumped on no news. But the move wasn't entirely surprising.
Spectrum's stock got a huge lift from its mid-stage lung cancer drug candidate today.
Shares of the supermarket supplier surged after its earnings report, but the stock was down by this afternoon. Here's why.
Earnings beat expectations, but not all of the news is good for Cree today.
The specialist in mobile-device management software is down after posting underwhelming results and replacing its CEO.
The biopharma's lead drug candidate has strong potential based on a sneak peek at midstage trial data.
Third-quarter results came in above Wall Street's targets, and management expects a return to earnings growth in the next quarter.
The company has concluded its strategic alternatives process by selling a business it acquired earlier this year. Investors don't seem thrilled with the drama.
Shares spike on no news, but that happens in the land of small-cap biotechs.
Netflix's continued popularity could undermine MoviePass' ability to acquire millions of subscribers.
A big rally driven by news of a favorable court ruling is unraveling now that all the details are known.
Is there a specific reason for Xunlei stock's rise on Tuesday?
Shares have seen increased volatility despite the company gaining its first-ever marketing approval recently.
Wall Street analyst cuts price target, so Spirit stock goes up. (Wait. What?)
Sometimes even a drop in profits still pleases investors.
The retailer continued to slide after a major investor said he would step down from its board.
Traders flee after the company announces that it is merging with a privately held drugmaker.
TransEnterix's stock keeps moving higher in the wake of the FDA clearing its novel robotic surgery device.
Shares are up, but that doesn't tell the whole story of TerraForm Power today.
The bitcoin revolution is even turning old "shorts" long.
Third-quarter results came in strong.
22nd Century Group may be ready to take flight as a result of the FDA's latest tobacco harm reduction initiative.
The patent litigation company jumped, then slumped, after a significant favorable judgment in its ongoing Apple case.
A key investor is leaving the department store chain's board.
NRD Capital, an Atlanta-based private equity firm, agreed to acquire struggling restaurant chain Ruby Tuesday for $2.40 per share -- here are the details.
In the wake of a challenging month, the company offered up some good news that kick-started shares today.
FDA approval for its lead drug candidate may have just become a bit more uncertain.
Positive phase 3 data for Cabometyx in liver cancer sends shares of the biotech higher.
An analyst sees the company's weak growth outlook as a major problem for the stock.